NEWS COMMENTARY

Evolve BioSystems raises $55 million to expand its probiotics for infant health application

Published:
February 12, 2021
Services:
CPG More...
Priorities:
“Better-for-You” Transformation More...
Topics:
Consumer Diagnostics | Consumer Genomics  More... | Microbiome Analysis | Microbiome Modulation | Opportunities in Wellness | Personalized Nutrition | Point-of-Care Diagnostics | Skin Microbiome
Activities:
Investment
by Harini Venkataraman
Average importance

This Series D funding round was led by Cargill and Manna Tree and will help Evolve expand the market reach of its probiotic supplement targeting infant health. This investment also signals Cargill's sustained interest in the microbiome space, coming on the heels of its previous investment in Seventure Partners' microbiome fund. Evolve (Lux Take: Engage) is developing probiotics based on Bifidobacterium infantis to address infant gut dysbiosis. In combination with human milk oligosaccharides, the use of pre- and probiotics for the infant gut microbiome is a fast-growing application area. Clients, the microbiome modulation space offers a number of opportunities in the realm of health and wellness, beyond just gut health.

For the original news article, click here .


Further Reading

Pendulum Therapeutics raises $54 million for probiotic supplement targeting diabetes management

News Commentary | May 05, 2021

Led by Meritech Capital, this Series C round brings the company's funding to $111 million, allowing it to scale up manufacturing and expand sales of its first product. In January 2020, Pendulum Therapeutics (previously known as Whole Biome) launched Glucose Control, a probiotic blend consisting of ... Not part of subscription

Build and buy: Chr. Hansen's strategy to solidify its microbiome business

Case Study | October 15, 2021

Chr. Hansen is a key player in the nutritional and health ingredients landscape. In particular, the company's human health and probiotics segment is well‑known for developing and launching a number of key probiotic strains like Lactobacillus rhamnosus and Bifidobacterium, BB‑12. Over the years, the ... Not part of subscription

ADM to strengthen its gut health portfolio by acquiring Deerland Probiotics & Enzymes

News Commentary | November 11, 2021

ADM has been keen on growing its gut health offerings, starting with the acquisition of Protexin in 2018. Over the past couple of years, the company has also expanded its existing product categories to accommodate new application areas. While the financial details of Deerland's acquisition are not ... To read more, click here.